BioCentury
ARTICLE | Company News

Intercytex Group plc, Pfizer deal

December 7, 2009 8:00 AM UTC

Pfizer acquired undisclosed stem cell therapy assets from Intercytex's Axordia Ltd. subsidiary for $750,000. Intercytex will use the funds to support ongoing costs. In July, the biotech reduced headcount and said it had received offers to acquire undisclosed parts of the business. In March, Intercytex discontinued development of its lead Cyzact (ICX-PRO), a second-generation allogeneic human dermal fibroblast in fibrin-based gel matrix, after it missed the primary endpoint in a Phase III trial to treat venous leg ulcers (see BioCentury, July 13). ...